<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SULFACETAMIDE SODIUM - sulfacetamide sodium ointment </strong><br>Fera Pharmaceuticals, LLC<br></p></div>
<h1>SULFACETAMIDE SODIUM OPHTHALMIC OINTMENT USP, 10%
Sterile    Rx Only</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION:</h1>
<br>Sulfacetamide Sodium Ointment USP, 10%, is a sterile, topical anti-bacterial agent for ophthalmic use.  Each gram contains Sulfacetamide Sodium USP, 100 mg in an ointment base of white petrolatum and mineral oil.<p class="First">Sulfacetamide sodium is an odorless, white, crystalline powder.  It is freely soluable in water, sparingly soluble in alcohol, and practically insoluble in benzene, chloroform, and ether.  Chemically it is <span class="Italics">N</span>-sulfanilylacetamide monosodium salt monohydrate, and is represented by the following structural formula:</p>
<div class="Figure"><img alt="Fera Sulfacetamide Sodium Ointment Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=26983557-e3e8-477f-bb63-64f04b1606eb&amp;name=7caa1fd5-debb-4de1-be58-a137e17bea0c-01.jpg"></div>
<p></p>
<p><br><br>Molecular Formula: C<span class="Sub">8</span>H<span class="Sub">9</span>N<span class="Sub">2</span>NaO<span class="Sub">3</span>S•H<span class="Sub">2</span>O<br>Molecular Weight 254.24<br></p>
<p></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY:</h1>
<br><div class="Section" data-sectionCode="49489-8">
<a name="section-2.1"></a><p></p>
<h2>Microbiology:</h2>
<p class="First">The sulfonamides are bacteriostatic agents and the spectrum of activity is similar for all.  Sulfonamides inhibit bacterial synthesis of dihydrofolic acid by preventing the condensation of pteridine with aminobenzoic acid through competitive inhibition of the enzyme dihydropteroate synthetase.  Resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> have altered dihydropteroate synthetase with reduced affinity for sulfonamides or produce increased quantities of aminobenzoic acid.</p>
<p>Topically applied sulfonamides are considered active against susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following common bacterial eye pathogens:  <span class="Italics">Escherichia coli, </span><span class="Italics">Staphylococcus aureus,</span><span class="Italics">Streptococcus pneumoniae, Streptococcus </span>(viridans group)<span class="Italics">, </span><span class="Italics">Haemophilus influenzae,Klebsiella </span>species, and <span class="Italics">Enterobacter</span> species.</p>
<p>Topically applied sulfonamides do not provide adequate coverage against <span class="Italics">Neisseria</span> species, <span class="Italics">Serratia marcescens</span> and <span class="Italics">Pseudomonas aeroginosa.</span>  A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs.<br></p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE:</h1>
<p class="First">For the treatment of <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> and other superficial ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to susceptible microorganisms:</p>
<p>    <span class="Italics">Escherichia coli, </span><span class="Italics">Staphylococcus aureus, </span><span class="Italics">Streptococcus pneumoniae, </span><span class="Italics">Streptococcus </span>(viridans group)<span class="Italics">, Haemophilus influenzae, Klebsiella</span> species, and<span class="Italics"><span class="Italics"><span class="Italics"> Enterobacter</span></span></span> species<span class="Italics"><span class="Italics">.</span></span></p>
<p>Topically applied sulfonamides do not provide adequate coverage against <span class="Italics">Neisseria</span> species, <span class="Italics">Serratia marcescens</span> and <span class="Italics">Pseudomonas aeroginosa</span>.  A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs.<br></p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS:</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to sulfonamides or to any ingredient of the preparation.<br></p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-5"></a><p></p>
<h1>WARNINGS:</h1>
<p class="First">FOR TOPICAL EYE USE ONLY-NOT FOR INJECTION.</p>
<p>FATALITIES HAVE OCCURRED, ALTHOUGH RARELY, DUE TO SEVERE REACTIONS TO SULFONAMIDES INCLUDING <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">STEVENS-JOHNSON SYNDROME</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">TOXIC EPIDERMAL NECROLYSIS</span>, FULMINANT <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">HEPATIC NECROSIS</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">AGRANULOCYTOSIS</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">APLASTIC ANEMIA</span> AND OTHER <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">BLOOD DYSCRASIAS</span>.  Sensitizations may recur when a sulfonamide is readministered, irrespective of the route of administration.  Sensitivity reactions have been reported in individuals with no prior history of sulfonamide <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.  At the first sign of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or other serious reaction, discontinue use of this preparation.<br></p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First"><br></p>
<div class="Section" data-sectionCode="34072-9">
<a name="section-6.1"></a><p></p>
<h2>General:</h2>
<p class="First">Prolonged use of topical anti-bacterial agents may give rise to overgrowth of nonsusceptible organisms including fungi.  <span class="product-label-link" type="condition" conceptid="4207042" conceptname="Viral resistance">Bacterial resistance</span> to sulfonamides may also develop.  <br></p>
<p>Ophthalmic ointments may retard corneal <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing.</p>
<p>The effectiveness of sulfonamides may be reduced by the para-aminobenzoic acid present in the purulent exudates.  Sensitization may recur when a sulfonamide is readministered irrespective of the route of administration, and cross-sensitivity between different sulfonamides may occur.</p>
<p>At the first sign of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, increase in <span class="product-label-link" type="condition" conceptid="4145093" conceptname="Purulent discharge">purulent discharge</span>, or aggravation of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, the patient should discontinue use of the medication and consult a physician (see <span class="Bold">WARNINGS</span>).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-6.2"></a><p></p>
<h2>Information for patients:</h2>
<p class="First">To avoid contamination, do not touch tip of container to eye, eyelid, or any surface.<br></p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-6.3"></a><p></p>
<h2>Drug Interactions:</h2>
<p class="First">Sulfacetamide preparations are incompatible with silver preparations.<br></p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-6.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility:</h2>
<p class="First">No studies have been conducted in animals or in humans to evaluate the possibility of these effects with ocularly administered sulfacetamide.  Rats appear to be especially susceptible to the goitrogenic effects of sulfonamides, and long-term oral administration of sulfonamides has resulted in thyroid malignancies in these animals.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-6.5"></a><p></p>
<h2>Pregnancy:</h2>
<p class="First"><span class="Underline">Teratogenic effects</span>.  Pregnancy Category C<span class="Italics"><span class="Italics">.</span> </span> Animal reproduction studies have not been conducted with sulfonamide ophthalmic preparations.  <span class="product-label-link" type="condition" conceptid="4326231" conceptname="Kernicterus">Kernicterus</span> may occur in the newborn as a result of treatment of a pregnant woman at term with orally administered sulfonamides.  There are no adequate and
well controlled studies of sulfonamide ophthalmic preparations in pregnant women and it is not known whether topically applied sulfonamides can cause fetal harm when administered to a pregnant woman.  This product should be used in pregnancy only if the potential benefit justifies the potential
risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7"></a><p></p>
<h1>Nursing Mothers:</h1>
<br>Systemically administered sulfonamides are capable of producing <span class="product-label-link" type="condition" conceptid="4326231" conceptname="Kernicterus">kernicterus</span> in infants of lactating women.  Because of the potential for the development of <span class="product-label-link" type="condition" conceptid="4326231" conceptname="Kernicterus">kernicterus</span> in neonates, a decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother.<br>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8"></a><p></p>
<h1>Pediatric Use:</h1>
<br>Safety and effectiveness in children below the age of two months have not been established.<br><br>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS:</h1>
<br><p class="First">Bacterial and fungal <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulcers</span> have been developed during treatment with sulfonamide ophthalmic preparations.</p>
<p>The
most frequently reported reactions are local irritation, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> and burning.  Less commonly reported reactions include non-specific <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>,
<span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival hyperemia</span>, <span class="product-label-link" type="condition" conceptid="442777" conceptname="Generalized infection during labor">secondary infections</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.  Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, fulminant <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, and other <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span> (see <span class="Bold">WARNINGS</span>).<br></p>
<p><span class="Italics">To
report SUSPECTED ADVERSE REACTIONS, </span>contact Fera Pharmaceuticals, LLC
at (414) 434-6604, Monday - Friday 9am-5pm EST, or FDA at
1-800-FDA-1088 or www.fda.gov/medwatch.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION:</h1>
<br><span class="Bold">For <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> and other superficial ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>:</span>  Apply a small amount (approximately one-half inch ribbon) into the conjunctival sac(s) of the affected eye(s) every three to four hours and at bedtime.  Dosages may be tapered by increasing the time interval between doses as the condition responds.  The ointment may be used as adjunct to the solution.  The usual duration of treatment is seven to ten days.<br><br><br>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED:</h1>
<br>Sulfacetamide Sodium Ophthalmic Ointment USP, 10%,  is supplied in 3.5 gram (1/8 Oz) sterile, tamper evident tubes, NDC 48102-103-35.<br><p class="First">Store at 20<span class="Sup">o</span>-25<span class="Sup">o</span>C (68<span class="Sup">o</span>-77<span class="Sup">o</span>F) [See USP Controlled room temperature].</p>
<p><br><span class="Sup"></span></p>FERA<br><p>Mfd. for:</p>
<p><span class="Bold">Fera Pharmaceuticals, LLC</span></p>
<p>Locust Valley, NY  11560</p>
<p>PF10335A</p>
<p>R0212<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - CARTON</h1>
<br><div class="Figure"><img alt="Fera Sulfacetamide Sodium Ophthalmic Ointment Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=26983557-e3e8-477f-bb63-64f04b1606eb&amp;name=7caa1fd5-debb-4de1-be58-a137e17bea0c-02.jpg"></div>
<br><p class="First">FERA<br></p>
<p>NDC 48102-103-35</p>
<p>STERILE        Rx only</p>
<p>Sulfacetamide</p>
<p>Sodium</p>
<p>Ophthalmic</p>
<p>Ointment</p>
<p>USP, 10%<br><span class="Sup"></span></p>
<br>Net wt. 3.5 g (1/8 oz)</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - TUBE</h1>
<br><div class="Figure"><img alt="Fera Sulfacetamide Sodium Ophthalmic Ointment Tube Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=26983557-e3e8-477f-bb63-64f04b1606eb&amp;name=7caa1fd5-debb-4de1-be58-a137e17bea0c-03.jpg"></div>
<p class="First">FERA<br></p>
<p>NDC 48102-103-35</p>
<p>STERILE      Rx only</p>
<p>Sulfacetamide</p>
<p>Sodium</p>
<p>Ophthalmic</p>
<p>Ointment</p>
<p>USP, 10%<br></p>
<p>Each gram contains:</p>
<p>sulfacetamide sodium USP,</p>
<p>100 mg in an ointment base of <br></p>
<p>white petrolatum and mineral oil.</p>
<p>Net wt. 3.5 g (1/8 oz)<br></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SULFACETAMIDE SODIUM 		
					</strong><br><span class="contentTableReg">sulfacetamide sodium ointment</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:48102-103</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SULFACETAMIDE SODIUM</strong> (SULFACETAMIDE) </td>
<td class="formItem">SULFACETAMIDE SODIUM</td>
<td class="formItem">100 mg  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MINERAL OIL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PETROLATUM</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:48102-103-35</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">3.5 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA080029</td>
<td class="formItem">03/01/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Fera Pharmaceuticals, LLC
							(831023713)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Fera Pharmaceuticals, LLC (831023713)</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 2/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>7caa1fd5-debb-4de1-be58-a137e17bea0c</div>
<div>Set id: 26983557-e3e8-477f-bb63-64f04b1606eb</div>
<div>Version: 1</div>
<div>Effective Time: 20120224</div>
</div>
</div> <div class="DistributorName">Fera Pharmaceuticals, LLC</div></p>
</body></html>
